Friday’s Furry Friends: Dana, ReeseTaylor Swift shocker: New album, “The Tortured Poets Department,” is actually a double album
Over 30 million Americans have diabetes. Photo via CBS News. The injection of a lifetime is in the works. A revolutionary drug could soon be approved to delay Type 1 diabetes. We looked at how the shot would work, what it will take for it to become a reality and spoke to those for whom this would be a game changer. About three years ago, doctors diagnosed Stephanie Rochelle’s son, Finn, with Type 1 diabetes. “They finger pricked him, and his sugar then was 380,” Rochelle said. Rochelle says — because Finn was so little — doctors had difficulty drawing his blood and had to pin him down. But the strain followed the family outside of the hospital too. “Eight, 10, 12 finger pricks a day. Eight, 10, 12 injections a day,” Rochelle explained. “I had to quit my job. I walked away from a very good career.” Rochelle says Finn needed constant care to manage his diabetes. But as he’s getting older, it’s getting easier. “He is understanding if I say, ‘Give yourself 50 carbs; treat yourself for 50 carbs,’” Rochelle said. “He knows what it is. At two, he obviously can’t do it himself.” A new drug is offering hope to families like Rochelle’s. Teplizumab is an injection that stops the immune cells that trigger Type 1 diabetes. Trial patients received two weeks of treatment. More than 900 day later, 50% of patients remained diabetes free. Back in May, and FDA advisory panel voted in favor of approving the drug. The FDA is expected to make a final decision Friday, July 2. Rochelle says, while it isn’t a cure, the extra time would be a great step forward. “I probably would have kept my job at least a little while longer until we could have figured out a solution to our problem,” Rochelle said. “The learning curve wouldn’t have been so big.” MORE: Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals FDA Advisory Committee Votes in Favor of the Benefits of Teplizumab Outweighing the Risks in Support of Approval to Delay Clinical Type 1 Diabetes (T1D) Teplizumab Participant Resources